 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.

Current Price	$8.24
Prev Close	$8.22
Open	$8.16
Dividend Yield	0.00%
50-Day Moving Average	$6.72
Beta	1.19
Avg. Volume	6.82M
PE Ratio	-3.42

52-Week High	$13.44
52-Week Low	$5.28
Market Capitalization	$1.84B
EPS	-$2.40
Price to Book	2.77
Revenue Per Employee	N/A
Enterprise Value/EBITDA	-1.93

IOVA Iovance Biotherapeutics Inc

About

Feed

Fundamentals

News